MabVax Therapeutics (PK) Stock Price - MBVXQ

0.00 (0.0%)
Best deals to access real time data!
DDE w/Realtime (Monthly)
Monthly Subscription
for only
Small Cap Pro
Monthly Subscription
for only
Canna Trader Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
MabVax Therapeutics Holdings Inc (PK) MBVXQ OTCMarkets Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
0.00 0.0% 0.023 0.00 0.00 0.00 0.023 20:00:00
Bid Price Ask Price Spread Spread % News
0.0188 0.03 0.0112 37.33% - -
Last Trade Time Type Quantity Stock Price Currency
- 0 $ 0.023 USD

MabVax Therapeutics (PK) Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 212.86k 9.25M 8.66M $ - $ - - -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
303.00 $ - 0.00% - -

more financials information »

MabVax Therapeutics (PK) News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical MBVXQ Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week0.
1 Month0.
3 Months0.0210.0230.020.02209851,2140.0029.52%
6 Months0.007750.0480.00570.014496326,0480.01525196.77%
1 Year0.050.06350.00370.014157527,984-0.027-54.0%
3 Years0.0610.100.00370.020550127,081-0.038-62.3%
5 Years0.0610.100.00370.020550127,081-0.038-62.3%

MabVax Therapeutics (PK) Description

MabVax Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on the development of antibody-based products and vaccines to address unmet medical needs in the treatment of cancer. MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers with the Company's proprietary vaccines. MabVax also has the exclusive license to the therapeutic vaccines from Memorial Sloan Kettering Cancer Center. In December 2015 MabVax received authorization from the U.S. Food and Drug Administration, or FDA, to proceed with initiation of a Phase I clinical trial with HuMab-5B1 MVT-5873 as a therapeutic treatment for pancreatic cancer. Patient enrollment in the Phase I clinical trial was initiated in the first quarter of 2016. In February 2016 MabVax announced the FDA had provided authorization to proceed with [Zr-89]-HuMab-5B1 MVT-2163, utilizing our fully human antibody product as a new generation PET scan cancer imaging agent. We expect patient enrollment for the new generation PET scan cancer imaging agent to begin in the second quarter of 2016. MabVax also has two cancer vaccines targeting recurrent sarcoma and ovarian cancer in proof-of-concept Phase II multicenter clinical trials. Additional information is available at

Your Recent History
MabVax The..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.